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Peripheral arterial disease (PAD) is well recognized as a marker for systemic atherosclerosis. Platelets play an essential role
in all stages of the disease, contributing to both thrombosis and the development of atherosclerosis. Medication regimens
to optimize outcomes in both patients who are to undergo revascularization and those who will be managed without
interventional therapy must address antiplatelet therapy. Given the common cardiovascular and cerebrovascular
comorbidities in patients with PAD, antiplatelet therapy has the potential to decrease thromboembolic events in addition
to improving patency after interventions. This clinical update reviews the current literature and recommendations for
antiplatelet therapy in patients with PAD. (J Vasc Surg 2014;60:1085-91.)Peripheral arterial disease (PAD) is a marker for athero- triggered by the shear stress of the turbulent ﬂow of athero-
sclerotic disease in other vascular beds and also encom-
passes a heterogeneous range of clinical presentations,
making recommendations for optimal medical therapy
challenging. Antiplatelet therapy has been a mainstay in
these patients and has been used to improve functional sta-
tus, to decrease cardiovascular morbidity and mortality,
and to improve patency of extremity revascularization.
Although an optimal medical regimen in patients with
PAD has not been deﬁnitively proved, consensus guidelines
recommend the use of single antiplatelet therapy in these
patients.1 Recent evidence suggests suboptimal compliance
and variation with regard to these recommendations in pa-
tients undergoing peripheral vascular interventions.2,3
Thus, careful analysis of the current peer-reviewed litera-
ture is required to determine the optimal treatment strategy
with antiplatelet agents in this complex group of patients.
THE SIGNIFICANCE OF PLATELETS IN
ATHEROTHROMBOTIC DISEASE
Hemostasis is the result of a highly regulated system
involving cellular membrane receptors, platelets, and the
coagulation cascade4 (Fig 1). Platelet activation consists of
a morphologic change creating a ﬂat plate-like structure to
increase cellular membrane surface area and to optimize
combination with ﬁbrin into a sturdier meshwork to solidify
the initial hemostatic plug. These same pathways arethe Division of Vascular Surgery, University of California, Los
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mulate in the vessel wall to form atheromas; activated
platelets recruit smooth muscle cells to form a ﬁbrinous
cap around the lipid-rich core, creating the atheromatous
plaque5,6 (Fig 2). All these mechanisms support the efﬁcacy
of antiplatelet therapy in the treatment of patients with PAD.
ASPIRIN AND CLOPIDOGREL
Aspirin, a nonselective cyclooxygenase inhibitor, at low
doses inhibits platelet generation of thromboxane A2 and
prevents platelet aggregation (Fig 3). Higher doses seem
to attenuate aspirin’s antithrombotic effect, and there is
no evidence that higher aspirin doses are more effective
than 75 to 325 mg daily.1 Clopidogrel is a thienopyridine
(Fig 3) with a wide variability of receptor inhibition. Its
main mechanism of action involves rapid absorption and
generation of a highly labile active metabolite by the cyto-
chrome P450 system, which irreversibly binds to the
platelet P2Y12 receptor as platelets pass through the liver.
1
The active metabolite of clopidogrel selectively inhibits the
binding of adenosine diphosphate (ADP) to its platelet
P2Y12 receptor and the subsequent ADP-mediated activa-
tion of the glycoprotein IIb/IIIa complex. Platelet aggre-
gation caused by agonists other than ADP is also
inhibited by clopidogrel by blocking the ampliﬁcation of
platelet activation by released ADP.1
It is estimated that approximately 4% to 30% of patients
treated with clopidogrel do not display an adequate anti-
platelet response. Patients with peripheral arterial occlusive
disease generally have multiple comorbidities, including
diabetes, hyperlipidemia, smoking, and other medications
like statins, proton pump inhibitors, and calcium channel
blockers, that may inﬂuence antiplatelet receptor inhibi-
tion.1 There is evidence that diabetic patients demonstrate
an attenuated response to clopidogrel compared with non-
diabetics.7 Proton pump inhibitors, calcium channel
blockers, and lipophilic statins have also been noted to1085
Fig 1. The formation of hemostasis and thrombosis after vessel wall injury. Injury to the vessel endothelium exposes
collagen and von Willebrand factor, which bind to speciﬁc platelet receptors. Collagen binds to glycoprotein (GP) Ia/
IIa, whereas von Willebrand factor binds to GPIb/IX. This process then leads to the activation of platelets and catalyzes
an intracellular signaling cascade, which results in the expression of the GPIIb/IIIa receptor. This receptor is the ligand
to ﬁbrinogen, augmenting platelet activation while stabilizing the hemostatic plug. Further, platelet activation also
consists of a morphologic change creating a ﬂatter plate-like structure to increase cellular membrane surface area. As this
process is under way, the coagulation cascade is also occurring by the exposure of tissue factor. Eventually, factor VII
along with factor III and thromboplastin culminate in the synthesis of thrombin. Thrombin then cleaves ﬁbrinogen into
insoluble ﬁbrin, which creates a sturdier meshwork to further solidify the initial hemostatic plug. This network of platelets
and polymerized ﬁbrin matures into a permanent plug preventing any further hemorrhage from the site of injury.
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Variable levels of active metabolite generation have also
been associated with smoking, leading to evidence for
decreased efﬁcacy of clopidogrel in these patients.1
THE ASYMPTOMATIC PATIENT: LOW TO
INTERMEDIATE RISK FOR CARDIOVASCULAR
DISEASE
There is no deﬁnitive Level I evidence demonstrating
a clear advantage of antiplatelet therapy for the primary
prevention of cardiovascular events in patients at moderate
to low risk. The Antithrombotic Trialists’ Collaborationstudied this question in a meta-analysis of the results of six
primary prevention trials that included 95,456 subjects
with a mean follow-up of 6.9 years.8 This study demonstrated
a 12% proportional reduction in the incidence of serious
vascular events due to a reduction of about a ﬁfth in nonfatal
myocardial infarction (MI). However, there was no net effect
on stroke between the aspirin and control groups, and vascular
mortality did not differ signiﬁcantly. In a similar meta-analysis
of 16 secondary prevention trials involving 17,000 patients at
high average risk comparing long-term aspirin vs control,
aspirin demonstrated a greater absolute reduction in serious
vascular events (6.7% vs 8.2% per year; P < .0001).
Fig 2. The formation of atheromatous plaque. Monocytes phagocytose cholesterol and cholesterol esters in the lipid-
rich environment, leading to foam cells; activated platelets release many factors, recruiting smooth muscle cells among
other cellular players. As the smooth muscle cells proliferate, they form a ﬁbrinous cap around the lipid-rich core. LDL,
Low-density lipoprotein; oxLDL, oxidized low-density lipoprotein.
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trials demonstrated a borderline signiﬁcant reduction in
all-cause mortality with aspirin therapy but no decrease in
cardiovascular mortality. The most recent consensus guide-
lines from the American College of Chest Physicians
recommend the use of low-dose aspirin (75-100 mg/d)
for primary prevention of cardiovascular events in patients
older than 50 years over no aspirin. These recommenda-
tions are based on Grade 2B evidence. A summary of the
most recent consensus guidelines from the American Col-
lege of Chest Physicians for patients with PAD is demon-
strated in the Table.
PATIENTS WITH EXISTING OR AT HIGH RISK
FOR CARDIOVASCULAR DISEASE
There is no convincing evidence in the peer-reviewed
literature that higher doses of aspirin are superior to lower
doses at reducing the risk of serious vascular events.1 With
regard to patients at high risk for adverse cardiovascular
events, the clinical effects of different aspirin doses have
been studied in randomized controlled studies. The United
Kingdom Transient Ischaemic Attack (UK-TIA) trialrandomized 2435 patients after transient ischemic attack
or ischemia stroke to receive doses of either aspirin or pla-
cebo. The study demonstrated that for aspirin doses of
300 and 1200 mg/d, no differences were noted in the
rates of MI, major stroke, or vascular death.1 In the Dutch
TIA Trial, there were no differences in the rates of MI,
stroke, or cardiovascular death in 3131 patients who
were randomized to receive doses of either 30 or
283 mg/d.9 Similar results were found in the Clopidogrel
Optimal Loading Dose Usage to Reduce Recurrent
Events/Optimal Antiplatelet Strategy for Interventions
(CURRENT-OASIS 7) trial, which randomized 25,086
patients with acute coronary syndromes to both high-
and low-dose aspirin. This study demonstrated that
30 days of treatment with 300 to 325 mg/d of aspirin
was no more effective than low-dose aspirin (75-
100 mg/d) in preventing stroke, MI, and cardiovascular
death.10
In patients at moderate to high risk of cardiovascular
events, the reduction in MI is closely balanced with an
increased risk of gastrointestinal and extracranial bleeding.
Multiple randomized controlled trials have compared
Fig 3. The mechanism of action of aspirin, clopidogrel, and cilostazol on platelet aggregation and the formation of
hemostasis. This ﬁgure highlights the different areas of activity on blood platelets by aspirin, clopidogrel, and cilostazol.
Aspirin, a nonselective cyclooxygenase inhibitor, at low doses inhibits platelet generation of thromboxane A2 and
prevents platelet aggregation. Clopidogrel is a thienopyridine with a wide variability of receptor inhibition. The anti-
platelet effect of clopidogrel is caused by an inhibition of the binding of adenosine diphosphate (ADP) to its platelet
receptors and more speciﬁcally to the low-afﬁnity receptors, the high-afﬁnity binding sites being unaffected by clopi-
dogrel. Cilostazol is a phosphodiesterase 3 inhibitor that inhibits platelet activation and relaxes vascular smooth muscle.
AC, Adenylate cyclase; AMP, adenosine monophosphate; cAMP, cyclic adenosine monophosphate; CYP, cytochrome
P450; GP, glycoprotein; PI3K, phosphoinositide 3-kinase; PKA, protein kinase A.
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atherothrombotic risk. These include patients with known
cerebrovascular, cardiovascular, and peripheral vascular dis-
ease and patients with signiﬁcant risk factors associated
with atherosclerosis. A subgroup analysis of the Clopidog-
rel for High Atherothrombotic Risk and Ischemic Stabili-
zation, Management, and Avoidance (CHARISMA) trial,
which enrolled patients with either established athero-
thrombotic disease or multiple risk factors to either dual
antiplatelet therapy (clopidogrel and aspirin) or aspirin
alone, demonstrated a 7.1% relative risk reduction in MI,
stroke, or cardiovascular death during a median of
28 months with a dual antiplatelet regimen.11 In addition,
dual therapy provided some beneﬁt over aspirin alone in
patients with PAD for the rate of MI and rate of hospital-
ization for ischemic events. The rates of severe, fatal, or
moderate bleeding did not differ between groups;however, the rate of minor bleeding was signiﬁcantly
increased with dual therapy. The Clopidogrel in Unstable
angina to prevent Recurrent Events (CURE) trial
compared dual therapy with clopidogrel and aspirin to
aspirin alone in patients with acute coronary syndromes
and found a 2.1% risk reduction in composite cardiovascu-
lar death, MI, and stroke but also a 1.0% increased risk of
major bleeding.12 As a result, only patients with acute
non-ST coronary syndrome demonstrated advantages
with clopidogrel and aspirin therapy, and only in this group
do the beneﬁts outweigh the risk of bleeding.
Conversely, in the Clopidogrel vs Aspirin in Patients at
Risk for Ischemic Events (CAPRIE) study, three groups of
patients (n ¼ 19,185) at high risk of a recurrent ischemic
event (recent MI, recent stroke, symptomatic PAD) were
randomized to receive clopidogrel vs aspirin.13 Clopidogrel
signiﬁcantly reduced the relative risk of MI, ischemic
Table. Summary of consensus guidelines from the American College of Chest Physicians for patients with peripheral
arterial disease (PAD)
Patient category
Level of peer-reviewed
evidence
American College of Chest Physicians consensus
recommendation
The asymptomatic patient with low to intermediate
risk for cardiovascular event
Grade 2B d Low-dose aspirin (75-100 mg) for primary prevention
of cardiovascular event in patients >50 years of age
Patients with symptomatic PAD (including patients
before and after peripheral arterial bypass surgery or
percutaneous transluminal angioplasty)
Grade 1A d Long-term aspirin (75-100 mg/day) or clopidogrel
(75 mg/d)
Patients undergoing peripheral percutaneous
transluminal angioplasty with stenting
Grade 2C d Single rather than dual antiplatelet therapy
recommended
Patients with refractory claudication despite exercise
therapy and smoking cessation
Grade 2C d Addition of cilostazol (100 mg bid) to aspirin
(75-100 mg/d) or clopidogrel (75 mg/d)
Modiﬁed from Alonso-Coello P, Bellmunt S, McGorrian C, Anand SS, Guzman R, Criqui MH, et al. Antithrombotic therapy in peripheral artery disease:
Antithrombotic Therapy and Prevention of Thrombosis, 9th Ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest
2012;141:e669s-90s.
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alone. Thus, on the basis of the results of this study, long-
term administration of clopidogrel in patients with athero-
sclerotic peripheral vascular disease was deemed more effec-
tive than aspirin in reducing the combined risk of ischemic
stroke, MI, or vascular death. Clopidogrel was also deemed
as safe as medium-dosed aspirin in these patients.10
Another antiplatelet agent that has demonstrated
beneﬁt in patients with peripheral vascular disease is cilosta-
zol. This drug is a phosphodiesterase 3 inhibitor that in-
hibits platelet activation and relaxes vascular smooth
muscle. Multiple meta-analyses have demonstrated that cil-
ostazol increases both the maximum and pain-free walking
distance in intermittent claudicants, decreases the risk of
thrombotic events, and decreases the risk of restenosis in
patients after stenting of either coronary or peripheral ar-
teries, with a reported increase in their quality of life.14
The most recent consensus guidelines by the American Col-
lege of Chest Physicians recommend the addition of cilosta-
zol 100 mg twice per day to either aspirin (75-100 mg/d)
or clopidogrel (75 mg/d) in patients with refractory inter-
mittent claudication based on Grade 2C evidence.15
ANTIPLATELET THERAPY AND BLEEDING IN
THE PERIOPERATIVE PERIOD
A main concern with antiplatelet therapy in the periop-
erative period is increased risk of bleeding. However, with-
drawal of antiplatelet therapy may also cause a rebound
hypercoagulable state.16 Compounded with the prothrom-
botic effects of surgery itself, these patients may be at risk
for thrombotic complications in the absence of antiplatelet
therapy.
A recent review by the Vascular Study Group of New
England of 10,406 patients who underwent carotid endar-
terectomy, lower extremity bypass, and endovascular or
open abdominal aneurysm repair demonstrated no differ-
ence in rates of reoperation for bleeding or for transfusion
with aspirin alone, clopidogrel alone, or aspirin and clopi-
dogrel together.17 Whereas some studies have demon-
strated increased bleeding potential in patients
undergoing cardiac surgery with antiplatelet therapy, thishas not been demonstrated in peripheral arterial surgery.
The Clopidogrel and Acetylsalicylic acid in bypass Surgery
for Peripheral Arterial disease (CASPAR) trial also demon-
strated no signiﬁcant increase in severe bleeding complica-
tions in patients receiving clopidogrel, suggesting that it
can be safely continued in the perioperative period.18
ANTIPLATELET THERAPY AFTER SURGICAL
REVASCULARIZATION
Peripheral arterial bypass grafts induce platelet accumu-
lation along their walls, regardless of conduit used.19 Intact
vascular endothelium is inherently resistant to platelet accu-
mulation, contributing to the marked difference between
autogenous and prosthetic grafts.
Goldman et al randomized patients undergoing a fem-
oropopliteal bypass to placebo or dual antiplatelet therapy
with aspirin and dipyridamole.19 Isotope-labeled platelets
demonstrated platelet burden within the graft at 7 days
postoperatively. Dual antiplatelet therapy signiﬁcantly
decreased platelet aggregation in prosthetic grafts,
although the study was not powered to demonstrate a sig-
niﬁcant difference in vein grafts. In a subsequent study, the
authors also demonstrated an increased 1-year patency with
aspirin and dipyridamole vs placebo alone.20 Ameta-analysis
by the Antithrombotic Trialists’ Collaboration demon-
strated that aspirin conferred a risk reduction of 43% of pe-
ripheral artery or graft occlusion after revascularization,
whereas a Cochrane review demonstrated a risk reduction
of 41% of graft occlusion at 1 year.8,21 Dextran has also
been demonstrated in randomized multicenter trials to in-
crease early patency in high-risk peripheral bypasses as well
as to decrease platelet aggregation on graft surfaces.22
There is signiﬁcant Level I evidence supporting the
routine use of aspirin in all patients undergoing infraingui-
nal bypass.23 The Dutch Bypass Oral Anticoagulants or
Aspirin (BOA) study randomized 2690 patients who had
undergone infrainguinal revascularization to receive either
oral anticoagulants or aspirin daily.24 With 21 months of
follow-up, there was no difference in graft occlusions over-
all, but a subgroup of vein bypasses treated with anticoagu-
lants had a risk reduction of thrombosis of 31% for
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compared with aspirin. Prosthetic grafts demonstrated a
risk reductionwith aspirin of 23% for femoropopliteal targets
and 31% for pedal targets. Anticoagulants were also associ-
atedwith nearly double the risk of hemorrhage and 3.5 times
the risk of hemorrhagic stroke compared with aspirin.
In a Cochrane meta-analysis of studies comparing
aspirin and placebo in patients undergoing infrainguinal
bypass surgery, patients receiving aspirin demonstrated a
statistically signiﬁcant absolute risk reduction of graft
thrombosis of 8.2%.25 This study, which compared aspirin
with and without dipyridamole to placebo after infraingui-
nal revascularization, demonstrated a statistically signiﬁcant
decrease in primary occlusions (odds ratio, 0.59; 95% con-
ﬁdence interval, 0.45-0.79) for all grafts, with no signiﬁ-
cant difference for vein bypasses but a higher effect on
prosthetic grafts (odds ratio, 0.22; 95% conﬁdence interval,
0.12-0.38).22 The effect of aspirin on cardiovascular out-
comes and survival was small and not statistically signiﬁcant.
The CASPAR trial was a multicenter, double-blinded,
randomized controlled study comparing dual antiplatelet
therapy with clopidogrel and aspirin and monotherapy
with aspirin alone in patients undergoing below-knee by-
passes.15 Dual therapy demonstrated no beneﬁt over
aspirin alone; however, subgroup analysis suggested a
beneﬁt to dual therapy with prosthetic grafts (35% decrease
in the relative risk of graft occlusion, further intervention,
major amputation, or death) without any signiﬁcant in-
crease in major bleeds. There was no beneﬁt from dual an-
tiplatelet therapy in nonfatal stroke or composite
thrombotic events.18
EFFECTS OF PLATELETS AFTER ENDOVAS-
CULAR REVASCULARIZATION
Angioplasty interrupts arterial endothelium, initiating
platelet adhesion, smooth muscle proliferation, and intimal
hyperplasia.6 This is especially relevant given meta-analysis
results that reported a patency of endovascular intervention
of 49% at 3 years for infrapopliteal revascularization.26
These failures are due to thrombosis, spasm, and intimal
hyperplasia, which are dependent on platelet activation.6
Animal studies have demonstrated increased numbers of
platelets at angioplasty sites, peaking at 2 hours and
continuing up to 2 days after the procedure, suggesting
that antiplatelet agents need to be at therapeutic levels at
the time of intervention.27,28 Evidence also suggests that
placement of stents may lead to platelet activation.6
ANTIPLATELET THERAPY AFTER ENDOVAS-
CULAR REVASCULARIZATION
The peer-reviewed literature contains Level I evidence
that long-term aspirin use after peripheral artery percuta-
neous transluminal angioplasty with or without stenting
improves clinical outcomes. The 2012 American College
of Chest Physicians guidelines recommend using single-
agent antiplatelet therapy for all patients who undergo pe-
ripheral artery angioplasty, with or without stenting, on the
basis of Grade 1A evidence.15 They also recommend thatfor patients undergoing peripheral artery percutaneous
transluminal angioplasty with stenting, single rather than
dual antiplatelet therapy should be used on the basis ofGrade
2C evidence. ACochrane review demonstrated a 60% reduc-
tion of recurrent obstruction with aspirin combined with
dipyridamole compared with placebo at 12-month follow-
up.29 Antiplatelet therapy also demonstrated a superior ef-
fect on patency after femoropopliteal angioplasty compared
with vitamin K antagonists at 3, 6, and 12 months.
A recent blinded, randomized trial published in Circu-
lation studied outcomes after angioplasty with and without
stenting in patients receiving oral aspirin with or without
cilostazol.30 Two hundred patients with femoropopliteal
lesions were treated at 13 centers. Angiographic restenosis
rates were signiﬁcantly lower in the cilostazol group vs the
aspirin group at 12 months (20% vs 49%; P ¼ .0001). The
cilostazol group also had a signiﬁcantly higher event-free
survival at 12 months, although there were no differences
in cardiovascular event rates between the two groups.
OTHER MEDICATIONS
Other oral thienopyridines have also been used as anti-
platelet agents, mostly in association with coronary inter-
ventions, namely, ticagrelor and prasugrel. Ticagrelor is a
direct-acting P2Y12-ADP receptor blocker that also inhibits
adenosine uptake by red blood cells.31 Prasugrel, a third-
generation thienopyridine, has demonstrated a faster onset
of action, greater potency, and more consistent platelet in-
hibition than clopidogrel but with an increase in major,
life-threatening, and fatal bleeding.18,32 With increased
knowledge of mechanisms of resistance seen with aspirin
and clopidogrel, ticagrelor and prasugrel have been sug-
gested as alternative antiplatelet agents in these patients.33
However, caution must be taken in these circumstances
because mechanisms of resistance for prasugrel and ticagre-
lor are poorly understood.
Last, there are three approved intravenous glycoprotein
IIb/IIIa inhibitors (abciximab, eptiﬁbatide, tiroﬁban) that
have been used to prevent platelet aggregation after percu-
taneous coronary intervention. There is insufﬁcient evi-
dence in the current literature to make any deﬁnitive
recommendations about their safety and efﬁcacy with re-
gard to peripheral arterial occlusive disease.
CONCLUSIONS
While rates of vascular intervention have been
increasing, the developing optimal medical regimens in pa-
tients with PAD are becoming increasingly important.
Because of the integral function of platelets in the progres-
sion of thrombosis and atherosclerosis, optimal antiplatelet
guidelines are required. With regard to primary prevention
of atherothrombotic events in low-risk patients, the litera-
ture is still not clear whether the beneﬁts outweigh the
bleeding risks. In high-risk patients, in patients with prior
cardiovascular complications, and in patients undergoing
surgical and endovascular treatment, there is good evi-
dence supporting the use of long-term antiplatelet therapy.
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